Men's Health

Why Oncology Must Demand More From Its Trials

Why Oncology Must Demand More From Its Trials

Estimated reading time:6minutes

It’s undeniable that cancer care has been transformed over the past two decades.

Novel treatment approaches have improved outcomes for many patients across a wide range of cancers. While cancer is still considered a life-threatening illness, many cancers are now being managed as chronic conditions, with patients living longer than could ever have been imagined just a generation ago.

This progress should be celebrated.

But it also raises an important question: As cancer treatments advance and effective options continue to be discovered and developed, how should the scientific evidence supporting new therapies evolve to help physicians identify the best treatment for each patient?

Well-designed clinical trials are the basis for advancing oncology care, generating the robust evidence of efficacy and safety needed to support regulatory approvals and bring innovative treatments to patients.

As treatment options expand and standards of care evolve, however, physicians, patients, and payers have moved beyond the discussion of whether a therapy works to asking an increasingly complex question: How does it compare with existing options, and which patients stand to benefit most?

Answering these questions requires high-quality scientific evidence that sometimes extends even beyond the stringent requirements for regulatory approval.

Beyond regulatory success

Healthcare providers are increasingly faced with challenges when it comes to multiple approved therapies for a specific cancer or alternative dosing schedules for an oncology drug. Patients want to understand which treatment offers the greatest chance of long-term benefit. Insurance providers and healthcare systems are evaluating comparative value. Experts who develop treatment guidelines are determining how therapies should be used first and where each fits in a patient’s treatment journey.

In this environment, meeting a regulatory threshold should be only the beginning of the conversation.

Today, multiple stakeholders are looking for evidence that goes beyond demonstrating activity and instead helps guide real-world clinical decisions.

Four areas deserve particular attention:

1. Did the trial answer a meaningful clinical question?

Not all positive trials advance patient care equally.

Historically, demonstrating efficacy and securing approval were often the primary goals of clinical studies. Increasingly, however, physicians, patients and payers are looking for something more: evidence that helps determine which treatments provide the greatest benefit in real-world practice.

That raises an important question. Beyond studies specifically designed to confirm earlier results, did the trial generate new knowledge that could change patient care, or did it largely reinforce what the oncology community already knew?

As oncology treatment options continue to improve, the industry’s high bar for evidence should also rise. Studies that demonstrate meaningful clinical benefit, establish superiority over relevant standards of care, clarify treatment sequencing, or identify which patients benefit most can meaningfully influence clinical practice. By contrast, studies designed primarily to satisfy a regulatory requirement may generate less actionable information for physicians and patients making treatment decisions.

The goal is not to diminish the importance of approval. Rather, it is to ask whether a study leaves the oncology community with a clearer understanding of how to improve patient outcomes.

2. Does the trial reflect the patients who will ultimately be treated?

Clinical trials are most useful when the patients enrolled reflect the range of people who will ultimately receive the treatment in clinical practice.

Cancer patients are not a homogeneous population. Age, underlying health conditions, prior treatments and other clinical characteristics can influence how patients respond to therapy and experience side effects. Yet clinical trials may enroll populations that are younger, healthier or less clinically complex than the patients physicians encounter every day.

That can leave important questions unanswered. How will a treatment perform in an older adult? In someone managing multiple health conditions? In patients with more difficult-to-treat disease or who may be at greater risk for certain adverse events?

Building representative populations into clinical development from the outset can help close these gaps. That includes appropriate geographic and demographic diversity, but it also means enrolling the clinically relevant subpopulations who reflect the complexity of patients seen in real-world practice, including those historically underrepresented in clinical research.

As cancer care becomes more precise, representation matters more, not less. The strongest evidence will be evidence physicians can confidently apply to the patients sitting in front of them.

3. Was the therapy compared against today’s standard of care?

Comparator selection has become increasingly important in a rapidly evolving treatment landscape.

A clinical trial provides the greatest value when it compares a new therapy against the treatments physicians are most likely to use in practice. Yet oncology advances quickly. By the time results are reported, the standard of care may have evolved.

In some cases, the challenge extends beyond standards of care that evolve during a study. Questions have also emerged about trials that were initiated with comparator arms many physicians no longer viewed as the most relevant treatment option available.

While such approaches may satisfy regulatory requirements, they can leave clinicians with unanswered questions about how a new therapy performs against the treatments they are most likely to use in practice.

As treatment options continue to expand, comparative relevance is becoming just as important as statistical significance.

4. Have we followed patients long enough?

In chronic cancers, understanding long-term outcomes is essential.

Patients with diseases such as chronic lymphocytic leukemia (CLL) may live decades longer after initial treatment. Yet pivotal trial results are often celebrated after only a few years of follow-up.

Early readouts are important and can accelerate access to innovative medicines, but some of the questions that matter most to patients and physicians can only be answered over time.

How durable is the benefit? What toxicities emerge or accumulate after years of treatment? Do early advantages persist? How does treatment affect future options if the cancer returns? And what can patients expect from the treatment years later?

Answering those questions also requires rethinking how we monitor safety. The appropriate period for tracking adverse events should be scientifically informed by the known or anticipated safety profile and mechanism of action of the specific therapy, rather than defaulting to historical conventions established for treatments with different risk profiles. For some therapies, biological effects can persist or emerge well beyond the end of treatment, making continued observation important to understanding the full benefit-risk profile.

The industry’s responsibility should therefore extend beyond generating the evidence needed for approval. We should continue measuring, publishing and discussing the longer-term and patient-relevant data that give physicians and patients confidence in the outcomes they can expect over time.

A new measure of leadership

Taken together, these trends raise a broader question for the oncology community:

Did a trial resolve an open question in cancer care, or did it simply demonstrate that another drug works?

The answer matters because the future of oncology will not be defined solely by scientific innovation. It will be shaped by the quality and totality of the evidence used to support that innovation.

As oncology enters a new era, we as an industry must adopt a higher aspiration: not simply to develop the most drugs, but to generate the most useful evidence that enables better decisions and outcomes.

If a trial does not establish meaningful clinical benefit, if it does not reflect the patients who will ultimately rely on it, if it is not tested against relevant standards of care, or if it leaves critical questions unanswered years later, we must be willing to ask more of ourselves.

At BeOne Medicines, we’re building the world’s leading oncology company driven by scientific excellence. We design our studies to answer the questions physicians and patients actually face, not simply to clear the bar for approval.

After all, approval should be the beginning of the evidence story, not the end of it.

Leave a Reply

Your email address will not be published. Required fields are marked *